Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic Formulation Feasibility Study of Indacaterol/Glycopyrronium Easyhaler
NCT05288075Phase 1Completed
- Sponsor
- Orion Corporation
- Start
- Feb 2022
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of indacaterol and glycopyrrolate metered dose inhaler in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by Orion Corporation. Primary endpoints: Peak Plasma Concentration and Area Under the Curve (0-72h). Started Feb 2022; status: completed.
02
Drugs
indacaterolglycopyrrolate metered dose inhaler
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT05288075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05288075.